Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143620 |
| CAS No | NA |
| Mol.F. | C13H10D2N4O |
| Mol.Wt. | 242.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143621 |
| CAS No | NA |
| Mol.F. | C13H8D4N4O |
| Mol.Wt. | 244.3 g/mole |
| INV STATUS | In Stock |
| CAT No | SRC-N0143622 |
| CAS No | NA |
| Mol.F. | C18H17D4N3OS |
| Mol.Wt. | 331.5g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143623 |
| CAS No | NA |
| Mol.F. | C18H13D8N3OS |
| Mol.Wt. | 335.5 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143624 |
| CAS No | NA |
| Mol.F. | C17H12D3FN4O3S |
| Mol.Wt. | 377.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143625 |
| CAS No | NA |
| Mol.F. | C17H11D4FN4O3S |
| Mol.Wt. | 378.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143626 |
| CAS No | NA |
| Mol.F. | C14H13D8N3O4 |
| Mol.Wt. | 303.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143627 |
| CAS No | 1330180-56-7 |
| Mol.F. | C4HD8N3O |
| Mol.Wt. | 123.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143628 |
| CAS No | NA |
| Mol.F. | C25H23D3N2O2 |
| Mol.Wt. | 389.5 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143629 |
| CAS No | NA |
| Mol.F. | C10H9ClN2O |
| Mol.Wt. | 208.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143630 |
| CAS No | NA |
| Mol.F. | C22H35N3O6S |
| Mol.Wt. | 469.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143631 |
| CAS No | NA |
| Mol.F. | C15H19D3N2O3 |
| Mol.Wt. | 281.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143632 |
| CAS No | NA |
| Mol.F. | C14H16N6O |
| Mol.Wt. | 284.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143633 |
| CAS No | NA |
| Mol.F. | C17H18F3N7O2 |
| Mol.Wt. | 409.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143634 |
| CAS No | NA |
| Mol.F. | C5H7D5N2O |
| Mol.Wt. | 121.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143635 |
| CAS No | 1184996-41-5 |
| Mol.F. | C5H7D3N2O3 |
| Mol.Wt. | 149.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |